Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 17, 2007

Quidel In-Licenses Flu Antiviral Resistance and Detection Tool

  • Quidel gained exclusive, worldwide rights to the antiviral resistance microarray-based influenza detection technology (AVR-Chip) and the microarray-based influenza B detection technology (BChip) from the University of Colorado at Boulder (CU-Boulder).

    "Exclusive access to molecular-based technologies for influenza B diagnostics and for detection of antiviral resistance, greatly complements our ongoing progress with our MChip technology for influenza A, which was licensed in December 2006 from CU-Boulder, " states Caren Mason, president and CEO.

    The AVR-Chip can identify mutations that may confer resistance to antiviral reagents and may then facilitate proper influenza treatment decisions. The BChip can detect influenza B virus strains. In a study of 62 influenza B virus samples from 19 countries, dating from 1945 to 2005, as well as five negative control samples, the BChip exhibited 97% sensitivity and 100% specificity with no false positives, according to Quidel.

  • You’re all set! Thank you for subscribing to GEN Highlights.